Dupilumab Therapy for EGIDs
Recruiting
Observational Study
Eosinophilic Gastrointestinal Disorders (EGIDs)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 1 – 18
- Sex
- Any
- Study type
- Observational
- Participants needed
- 20 (estimated)
- Sponsor
- Children's Hospital of Fudan University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a single-center observational study to investigate the efficacy and tolerability of dupilumab in children with refractory eosinophilic gastrointestinal disorders.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Clinical diagnosis of Refractory Peptic Ulcers
* with Refractory Eosinophilic Gastrointestinal Disorders
Exclusion Criteria:
* with Active Helicobacter pylori infection at present.
* with Inflammatory bowel disease
* with Parasite infection
* with Cancer
Contacts